| Literature DB >> 23422753 |
Jonathan M Flanagan1, Vivien Sheehan, Heidi Linder, Thad A Howard, Yong-Dong Wang, Carolyn C Hoppe, Banu Aygun, Robert J Adams, Geoffrey A Neale, Russell E Ware.
Abstract
Stroke is a devastating complication of sickle cell anemia (SCA), occurring in 11% of patients before age 20 years. Previous studies of sibling pairs have demonstrated a genetic component to the development of cerebrovascular disease in SCA, but few candidate genetic modifiers have been validated as having a substantial effect on stroke risk. We performed an unbiased whole-genome search for genetic modifiers of stroke risk in SCA. Genome-wide association studies were performed using genotype data from single-nucleotide polymorphism arrays, whereas a pooled DNA approach was used to perform whole-exome sequencing. In combination, 22 nonsynonymous variants were identified and represent key candidates for further in-depth study. To validate the association of these mutations with the risk for stroke, the 22 candidate variants were genotyped in an independent cohort of control patients (n = 231) and patients with stroke (n = 57) with SCA. One mutation in GOLGB1 (Y1212C) and another mutation in ENPP1 (K173Q) were confirmed as having significant associations with a decreased risk for stroke. These mutations were discovered and validated by an unbiased whole-genome approach, and future studies will focus on how these functional mutations may lead to protection from stroke in the context of SCA.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23422753 PMCID: PMC3630835 DOI: 10.1182/blood-2012-10-464156
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113